Patents Assigned to RevImmune, Inc.
  • COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
    Publication number: 20240382572
    Abstract: The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.
    Type: Application
    Filed: March 25, 2024
    Publication date: November 21, 2024
    Applicants: Cognate Bioservices, Inc., Northwest Biotherapeutics, Inc., The Regents of the University of California, RevImmune, Inc.
    Inventors: Marnix Leo Bosch, James Kelly Ganjei, Linda F. Powers, Linda M. Liau, Robert M. Prins
  • COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
    Publication number: 20240358807
    Abstract: A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.
    Type: Application
    Filed: October 18, 2023
    Publication date: October 31, 2024
    Applicants: Cognate Bioservices, Inc., Northwest Biotherapeutics, Inc., The Regents of the University of California, RevImmune, Inc.
    Inventors: Marnix Leo Bosch, James Kelly Ganjei, Linda F. Powers, Linda M. Liau, Robert M. Prins